Humanized cell line
View Patent ↗A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza virus, isolation and growth much more effectively than corresponding conventional (unmodified) cells or in corresponding human virus receptor-overexpressing cells, and the propagated viruses may maintain higher genetic stability than in the corresponding cells.
1. An isolated recombinant canine cell, comprising a reduced amount of cell surface β-galactoside α2,3 sialyl residues relative to a corresponding non-recombinant canine cell, wherein seven different β-galactoside α2,3 sialyltransferase (ST3) genes are mutated so as to reduce the amount of the cell surface β-galactoside α2,3 sialyl residues, wherein the seven different genes include ST3Gal-I, ST3Gal-II, ST3Gal-III, ST3Gal-IV, ST3Gal-V, ST3Gal-VI, and ST3Gal-II-like genes, and wherein the recombinant canine cell comprises an expression cassette encoding human β-galactoside α2,6 sialyltransferase I (ST6Gal-I) or ST6Gal-II, wherein the reduced amount of cell surface 3-galactoside α2,3 sialyl residues is the result of recombinase knock out mutation of the plurality of ST3 genes in the recombinant cell, and wherein the recombinant canine cell provides for increased human influenza virus replication relative to the corresponding non-recombinant canine cell.
2. The isolated recombinant cell of claim 1 further comprising an increased amount of human β-galactoside α2,6 sialyl residues relative to a corresponding non-recombinant canine cell.
3. The isolated recombinant cell of claim 1 which comprises an expression cassette encoding human β-galactoside α2,6 sialyltransferase I (ST6Gal-I).
4. A method of modifying the amount of cell surface β-galactoside α2,3 sialyl residues and human β-galactoside α2,6 sialyl residues on a canine cell, comprising:
mutating seven different β-galactoside α2,3 sialyltransferase (ST3Gal) genes, wherein the seven different genes include ST3Gal-I, ST3Gal-II, ST3Gal-III, ST3Gal-IV, ST3Gal-V, ST3Gal-VI, and ST3Gal-II-like genes, and overexpressing a human β-galactoside α2,6 sialyltransferase (ST6Gal) gene, in a parental canine cell so as to result in a modified canine cell having a reduced amount of cell surface β-galactoside α2,3 sialyl residues and an increased amount of human β-galactoside α2,6 sialyl residues on the surface of the modified cell relative to the corresponding parental canine cell.
5. The method of claim 4 wherein the mutations include one or more nucleotide insertions or one or more nucleotide deletions, or both, in the seven different ST3 genes.
6. The method of claim 4 wherein the modified cell comprises an expression cassette comprising a ST6Gal open reading frame.
7. A method of detecting or propagating an influenza virus, comprising:
infecting the recombinant cell of claim 2 with a sample having or suspected of having an influenza virus.
8. The method of claim 7 further comprising collecting progeny virus.
9. The method of claim 7 wherein the sample is from an avian or a mammal suspected of being infected with an influenza virus.
10. The method of claim 7 wherein the influenza virus is a human influenza virus.
11. The method of claim 7 wherein the influenza virus is an influenza A or B virus.
12. The method of claim 7 wherein the influenza virus is a H3 virus.
13. The method of claim 7 wherein the influenza virus is A/H1N1, A/H3N2, a B/Yamagata-lineage influenza B virus or a B/Victoria-lineage influenza B virus.
14. The method of claim 7 further comprising detecting whether the sample is infected with an influenza virus.
15. The method of claim 14 further comprising identifying the HA and/or NA subtype of the virus.
16. An isolated recombinant MDCK cell comprising a reduced amount of cell surface β-galactoside α2,3 sialyl residues relative to a parental MDCK cell, wherein seven β-galactoside α2,3 sialyltransferase (ST3) genes are mutated so as to reduce the amount of the cell surface β-galactoside α2,3 sialyl residues, and wherein the recombinant MDCK cell comprises an expression cassette encoding human β-galactoside α2,6 sialyltransferase I (ST6Gal-I) or ST6Gal-II, wherein the reduced amount of cell surface β-galactoside α2,3 sialyl residues is the result of recombinase knock out mutation of ST3Gal-I, ST3Gal-II, ST3Gal-III, ST3Gal-IV, ST3Gal-V, ST3Gal-VI, and ST3Gal-II-like genes in the recombinant MDCK cell.
17. The isolated recombinant canine cell of claim 1 which is infected with human influenza virus.